Publikation

Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma

Wissenschaftlicher Artikel/Review - 01.11.2009

Bereiche
PubMed
DOI

Zitation
Alkureishi L, McGurk M, Mortensen J, Poli T, Shoaib T, Sloan P, Sorensen J, Stöckli S, Thomsen J, Trifiro G, Werner J, Ross G, European Association of Nuclear Medicine Oncology Committee, Mamelle G, Leemans C, Lassmann M, Burak Z, Alvarez J, Ballinger J, Bilde A, Britten A, Calabrese L, Chiesa C, Chiti A, de Bree R, Gray H, Hunter K, Kovacs A, European Sentinel Node Biopsy Trial Committee. Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma. Annals of surgical oncology 2009; 16:3190-210.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Annals of surgical oncology 2009; 16
Veröffentlichungsdatum
01.11.2009
eISSN (Online)
1534-4681
Seiten
3190-210
Kurzbeschreibung/Zielsetzung

Involvement of the cervical lymph nodes is the most important prognostic factor for patients with oral/oropharyngeal squamous cell carcinoma (OSCC), and the decision of whether to electively treat patients with clinically negative necks remains a controversial topic. Sentinel node biopsy (SNB) provides a minimally invasive method for determining the disease status of the cervical node basin, without the need for a formal neck dissection. This technique potentially improves the accuracy of histologic nodal staging and avoids overtreating three-quarters of this patient population, minimizing associated morbidity. The technique has been validated for patients with OSCC, and larger-scale studies are in progress to determine its exact role in the management of this patient population. This document is designed to outline the current best practice guidelines for the provision of SNB in patients with early-stage OSCC, and to provide a framework for the currently evolving recommendations for its use. Preparation of this guideline was carried out by a multidisciplinary surgical/nuclear medicine/pathology expert panel under the joint auspices of the European Association of Nuclear Medicine (EANM) Oncology Committee and the Sentinel European Node Trial (SENT) Committee.